Invited commentary  by Powell, Janet T
effect of pravastatin on coronary events after myocardial infarction in
patients with average cholesterol levels. N Engl J Med 1996;335:
1001-9.
14. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW,
et al, for the West of Scotland Coronary Prevention Study Group.
Prevention of coronary heart disease with pravastatin in men with
hypercholesterolemia. N Engl J Med 1995;333:1304-7.
15. Scandinavian Simvastatin Survival Study Group. Randomized trial of
cholesterol lowering in 4,444 patients with coronary artery disease (4S).
Lancet 1994;344:1383-9.
16. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al,
for the AFCAPS/TexCAPS Reseach Group. Primary prevention of acute
coronary events with lovastatin in men and women with average choles-
terol levels. Results of AFCAPS/TEXCAPS. JAMA 1998;279:1615-22.
17. Prevention of cardiovascular events and death with pravastatin in pa-
tients with coronary heart disease and a broad range of initial cholesterol
levels. The Long-term Intervention with Pravastatin in Ischaemic Dis-
ease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
18. Schwartz GG, Oliver M, Ezekowitz MD, Ganz P, Waters D, Kane JP, et
al. Rationale and design of the Myocardial Ischemia Reduction with
Aggressive Cholesterol Lowering (MIRACL) study that evaluates ator-
vastatin in unstable angina pectoris and in non-Q-wave acute myocar-
dial infarction. Am J Cardiol 1998;81:578-81.
19. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters
D, et al, Myocardial Ischemia Reduction with Aggressive Cholesterol
Lowering (MIRACL) Study Investigators. Effects of atorvastatin on
early recurrent ischemic events in coronary syndromes: a randomized
controlled trial. JAMA 2001;285:1758-60.
20. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A
reductase inhibitor, improves endothelial function within 1 month.
Circulation 1997;95:1126-31.
21. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur
NK, et al. Cerivastatin, a hidroxymethylglutaryl coenzyme A reductase
inhibitor, improves endothelial function in elderly diabetic patients
within 3 days. Circulation 2001;104:376-9.
22. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas
AM, Pajak A. Myocardial infarction and coronary deaths in the World
Health Organization MONICA Project. Registration procedures, event
rates, and case-fatality rates in 38 populations from 21 countries on four
continents. Circulation 1994;90:583-612.
23. The Joint European Society of Cardiology/American College of
Cardiology Committee. Myocardial infarction redefined: a consen-
sus document of the Joint European Society of Cardiology/Ameri-
can College of Cardiology Committee for the redefinition of Myo-
cardial Infarction. J Am Coll Cardiol 2000;36:959-69.
24. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD,
Hochman JS, et al. ACC/AHA 2002 guideline update for the manage-
ment of patients with unstable angina and non-ST segment elevation
myocardial infarction. J Am Coll Cardiol 2002;40:1366-74.
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Pro-
tection Study of cholesterol lowering with simvastatin in 20,536 high-
risk individuals: a randomized placebo-controlled trial. Lancet 2002;
360:7-22.
Submitted Sep 24, 2003; accepted Dec 11, 2003.
Available online Feb 23, 2004.
INVITED COMMENTARY
Janet T. Powell, MD, PhD
Few patients with peripheral arterial disease have a disease-free
coronary circulation.1 Reconstructive procedures impose further
stress on the diseased coronary circulation, and cardiac morbidity
and mortality are recognized complications of vascular surgery.
The article by Durazzo et al in this issue of The Journal makes the
exciting suggestion that a short course of perioperative statins
could minimize these complications.
Before we all rush into new statin protocols, it is prudent to
examine the evidence carefully. One hundred patients, scheduled
for elective vascular procedures, were randomized to receive either
20 mg of atorvastatin or placebo, and the trial was designed to
show a reduction in postoperative cardiovascular events from 22%
to 1% within 6 months. This was a challenging target to set,
because even in patients at the highest cardiac risk undergoing
vascular surgery under general anaesthesia the perioperative car-
diovascular event rate is 34%.3 In the trial by Durazzo et al, 2
patients in the placebo group underwent more procedures under
spinal anaesthesia, 13 of 46 vs 5 of 44 in the atorvastatin group.
Therefore the incidence of events in the placebo group (26%) was
very high, unless spinal anesthesia was used, because these patients
were more likely to have American Society of Anesthesiologists
grade III and IV disease. In contrast, statin treatment reduced the
incidence of cardiovascular events to 8%, a result that just achieved
significance P .031. The excess events in the placebo group were
predominantly myocardial infarction and stroke. Survival analysis
showed a more convincing benefit in favor of atorvastatin treat-
ment. Confirmation of these results from other trials is awaited
eagerly.
So there is cautious optimism for an effective, simple, safe, new
treatment to minimize perioperative cardiac morbidity and mor-
tality after vascular surgery. Further support for this optimism
comes from retrospective analyses of in-hospital mortality after
vascular surgery and from late mortality after successful aortic
aneurysm repair.4,5 Statin therapy was more common in patients
discharged after vascular surgery than in those who died in hospital
(25% vs 8%; P .001).4 Late cardiovascular deaths after aneurysm
repair were reported in 9% of statin users compared with 38% in
nonusers.5 All of these studies reported that the benefit of statins is
independent of the use of -blockers.
How do statins produce these effects? Reduction of serum
lipid concentrations is an unlikely explanation for immediate ben-
eficial effects of statins on perioperative morbidity and mortality.
Two studies started with the hypothesis that statins exert their
beneficial perioperative effect by plaque stabilization.2,4 Statin
therapy also reduces postprocedural myocardial infarction and
death after percutaneous coronary intervention.6 In this context,
analysis of the serum C-reactive protein concentration indicated
that statins exert their effect by an anti-inflammatory mechanism,
statin therapy having most marked benefit in patients with the
highest preprocedural C-reactive protein concentrations.6
It is disappointing that only a minority of patients (15%) in the
trial by Durazzo et al2 continued to receive statin therapy after 45
days. Vascular surgeons must not ignore the mounting evidence
that statins benefit the cardiovascular health and survival of all
patients with peripheral arterial disease.7
REFERENCES
1. Hertzer NR, Beven EG, Young JR, O’Hara PJ, Ruschhaupt WF III,
Graor RA, et al. Coronary artery disease in peripheral vascular patients: a
classification of 1000 coronary angiograms and results of surgical man-
agement. Ann Surg 1984;199:223-33.
2. Poldermans D, Boersma E, Bax JJ, Thomson IR, Van De Ven LLM,
Blankensteijn JD, et al, for the Dutch Echocardiographic Cardiac Risk
Evaluation Applying Stress Echocardiography Study Group. The effect of
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 5 Durazzo et al 975
bisoprolol on perioperative mortality and myocardial infarction in high
risk patients undergoing vascular surgery. N Engl J Med 1999;341:
1789-94.
3. Poldermans D, Bax JJ, Kertai MD, Krenning B, Westerhout CM,
Schinkel AFL, et al. Statins are associated with a reduced incidence of
perioperative mortality in patients undergoing major noncardiac vascular
surgery. Circulation 2003;107:1848-51.
4. Kertai MD, Boersma E, Westerhout CM, van Domburg R, Klein J, Bax
JJ, et al. Association between long-term statin use and mortality after
successful abdominal aortic aneurysm surgery. Am J Med 2004;116:96-
103.
5. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, et
al. Relation of inflammation and benefit of statins after percutaneous
coronary interventions. Circulation 2003;107:1750-6.
6. Hiatt HR. Pharmacologic therapy for peripheral arterial disease and
claudication. J Vasc Surg 2002;36:1283-91.
JOURNAL OF VASCULAR SURGERY
May 2004976 Durazzo et al
